BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

11.09B

Market cap11.09B

Price-Earnings ratio

-552.95

Price-Earnings ratio-552.95

Dividend yield

—

Dividend yield—

Average volume

2.46M

Average volume2.46M

High today

$57.39

High today$57.39

Low today

$56.35

Low today$56.35

Open price

$56.86

Open price$56.86

Volume

1.43M

Volume1.43M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

The current BioMarin(BMRN) stock price is $57.23, with a market capitalization of 11.09B. The stock trades at a price-to-earnings (P/E) ratio of -552.95.

As of 2026-11-14, BioMarin(BMRN) stock has fluctuated between $56.35 and $57.39. The current price stands at $57.23, placing the stock +1.6% above today's low and -0.3% off the high.

The BioMarin(BMRN)'s current trading volume is 1.43M, compared to an average daily volume of 2.46M.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $70.98 at its peak.

BMRN News

Simply Wall St 21h

How A $1 Billion Quarter At BioMarin Pharmaceutical Has Changed Its Investment Story

BioMarin Pharmaceutical reported third quarter 2026 revenue of US$1,024.65 million and a wider net loss of US$122.83 million, and modestly lowered full year rev...

TipRanks 1d

BioMarin’s Noonan Syndrome Growth Study Update Raises Investor Questions

Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Study Overview: BioMarin Pharmaceutical is evaluating vosoritide in ch...

TipRanks 1d

BioMarin price target lowered to $103 from $119 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $103 from $119 and keeps an Overweight rating on the shares. The firm adjusted estimates an...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

More BMRN News

Simply Wall St 4d

BioMarin Pharmaceutical Following Q3 Results And A Guidance Cut Is It A Bargain

BioMarin Pharmaceutical (BMRN) is drawing fresh attention after third quarter 2026 results showed revenue of US$1,024.65 million, alongside a wider net loss and...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

KKR & Co

NRG Energy

Sprouts Farmers Market

Mastec

FTAI Aviation

Ocular Therapeutix

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.